AEON Biopharma, Inc. (AEON) Key Metrics
AEON valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $11.6M
- Enterprise value
- $12.4M
- P/E (TTM)
- —
- Forward P/E
- 1.2
- PEG ratio
- —
- Price / sales
- 97.2
- Price / book
- —
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.69
AEON key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAEON returns How much profit the business earns on the capital it uses.
AEON financial health Debt, liquidity and how easily interest is covered.
AEON efficiency & capital use Working capital cycle and where the cash goes.
AEON returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AEON debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AEON cash returned to shareholders
AEON key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Share price at fiscal year-end | $1.10 | $38.88 | $518.40 | $10.05 | $9.71 | — | — |
| Returns & profitability | |||||||
| Return on assets (ROA) | −901.4% | 841.2% | — | −610.6% | −402.4% | −48.6% | 151.2% |
| Return on tangible assets | −705.4% | — | — | −487.6% | −864.5% | −155.1% | 151.2% |
| Free cash flow margin | — | — | — | — | — | −375.7% | — |
| Income quality (OCF / net income) | — | −0.48 | — | — | — | — | −0.26 |
| Financial health | |||||||
| Total debt | $35.7M | $13.0M | $278,000 | $131.5M | $86.9M | $72.2M | $30.0M |
| Cash & short-term investments | $3.0M | $13,000 | $5.2M | $9.7M | $5.1M | $20.2M | $111.7M |
| Net debt | $32.7M | $12.9M | −$4.9M | $121.8M | $81.8M | $52.0M | −$81.8M |
| Debt / assets | 6.43 | 4.12 | 0.04 | 12.20 | 13.50 | 3.40 | 0.26 |
| Current ratio | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 | 4.85 | 6.41 |
| Quick ratio | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 | 4.85 | 6.41 |
| Interest coverage | — | — | — | — | — | — | -7.2 |
| Working capital | −$3.5M | −$12.6M | −$6.8M | −$72.7M | −$15.7M | $16.2M | $94.7M |
| Invested capital | −$22.3M | −$15.6M | −$157.9M | −$165.7M | −$153.2M | −$156.3M | −$148.9M |
| Tangible asset value | −$55.0M | −$28.6M | −$153.0M | −$270.4M | −$223.8M | −$203.2M | −$65.9M |
| Net current asset value | −$57.2M | −$30.1M | −$153.7M | −$271.4M | −$225.1M | −$204.1M | −$68.1M |
| Capital allocation | |||||||
| Dividends paid | — | — | — | — | — | — | $83.9M |
| Share buybacks (net) | — | — | — | — | — | $0 | $64,000 |
| Dividend payout ratio | — | — | — | — | — | — | 48.5% |
| Capex / revenue | — | — | — | — | — | 6.8% | 50.5% |
| Capex / depreciation | 0.05 | 0.00 | 0.00 | 4.50 | 56.67 | 56.67 | 1.35 |
| Stock-based compensation / revenue | — | — | — | — | — | 190.3% | 156.4% |
| R&D / revenue | — | — | — | — | — | 290.7% | 143.4% |
| SG&A / revenue | — | — | — | — | — | 460.2% | 1,371.4% |
| Efficiency | |||||||
| Days sales outstanding | — | — | — | — | — | 19.4 | 29.0 |
| Days payables outstanding | 16,031.9 | — | — | — | — | — | 374,125.0 |
| Cash conversion cycle (days) | — | — | — | — | — | — | -374,096.0 |
| Receivables turnover | — | — | — | — | — | 18.86 | 12.57 |
| Payables turnover | 0.02 | — | — | — | — | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Average receivables | — | — | — | — | — | $133,500 | $267,000 |
| Average payables | $3.4M | $4.6M | $5.6M | $4.5M | $1.6M | $1.5M | $1.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from AEON's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AEON valuation and financial ratios
It ended the year with $35.7 million of debt and $3.0 million in cash and short-term investments, net debt of $32.7 million.
See the AEON income statement, the AEON chart for price history, or the AEON stock overview for the latest quote and news.
AEON key metrics FAQ
How much debt does AEON Biopharma have?
AEON Biopharma had total debt of $35.7 million at the end of fiscal 2025.
What is AEON Biopharma's current ratio?
AEON Biopharma's current ratio was 0.49 at the end of fiscal 2025: current assets were 0.49 times current liabilities.